Baseline characteristics of enroled patients in the included studies
| Study | Demographics | Comorbidities (%) | Surgical Risk Score | ||||||||||
| Age mean/ med (SD/range) | Males (%) | Diabetes | Hyper- tension | AF | Kidney disease | Prior MI | Prior stroke | Prior CS | Prior PCI | STS score | Euro Score II | Log EuroScore (%) | |
| Paparella 201917 | |||||||||||||
| miAVR | 81 (5) | 43 | 29.5 | 87.5 | 19.6 | 14.4 | – | 1.0 | 9.9 | – | – | 3.0 (2.0–4.8)* | |
| TAVI | 81 (7) | 40.9 | 26.8 | 85.9 | 20.2 | 14.0 | 1.8 | 10.9 | 2.9 (2.2–4.4)* | ||||
| Furukawa 201818 | |||||||||||||
| miAVR | 78 (75–82) | 46.9 | 29.9 | 89.3 | 12.4 | – | 8.5 | 4.0 | 0.6 | – | 3.2 (2.7)† | 3.0 (2.3)† | – |
| TA–TAVI | 80 (75–84) | 49.1 | 28.8 | 88.7 | 10.7 | – | 6.2 | 5.7 | 1.1 | – | 3.6 (2.4)† | 3.4 (3)† | – |
| TF–TAVI | 79 (75–83) | 50.8 | 28.3 | 89.3 | 11.3 | – | 7.3 | 5.7 | 0.6 | – | 3.4 (2.2)† | 2.9 (0.5)† | – |
| Calle-Valda 201719 | |||||||||||||
| miAVR | 82.3 (4.8) | 56.0 | 22.0 | 82.0 | 8.0 | 2.0 | 6.0 | 10.0 | – | – | – | – | 8.3±3.4* |
| TAVI | 85.6 (4.9) | 46.0 | 32.0 | 92.0 | 32.0 | 18.0 | 16.0 | 20.0 | 15.8±5.4* | ||||
| Bruno 201722 | |||||||||||||
| RD-AVR‡ | 79.9 (3.6) | 50.0 | 20.0 | 83.3 | – | 10.0 | 10.0 | – | – | – | – | 5.01±0.87* | – |
| TAVI | 81.1 (3.3) | 56.7 | 31.0 | 73.3 | – | 16.7 | 6.9 | – | – | – | – | 5.19±1.15* | – |
| Hijri 201730 | |||||||||||||
| SAVR | 84.1 (3.2) | 47.8 | 19.3 | 79.5 | – | 5.1 | 9.0 | 5.7 | 18.6 | – | 5.58 (3.48)§ | – | – |
| TAVI | 86.2 (3.9) | 47.4 | 35.0 | 80.1 | 13.1 | 24.2 | 12.7 | 31.7 | 6.81 (4.54)§ | – | – | ||
| Nguyen 20179 ¶ | |||||||||||||
| Tokarek 2015/201623 | |||||||||||||
| TF–TAVI | 80 (73–83) | 35.9 | – | – | – | – | 10.5 | – | 15.4 | 46.2 | – | 3.4 (1.8–5.4)* | 9.5 (7–4)* |
| MT | 63 (54–73) | 66.0 | – | – | – | – | 16.0 | 0.0 | 10.0 | 1 (0.7–1.4)* | 2.7 (1.8–3.8)* | ||
| MS | 67 (57–77) | 45.4 | – | – | – | – | 13.6 | 2.3 | 11.4 | 1.2 (0.9–1.6)* | 4 (2.2–7)* | ||
| Miceli 201621 | |||||||||||||
| RT | 79 (4.5) | 30.1 | 27 | 86.5 | – | – | – | – | – | – | – | – | 16.1±11§ |
| TAVI | 78.8 (7.4) | 40.5 | 18.9 | 83.8 | 15.7±8.5§ | ||||||||
| Santarpino 201416 | |||||||||||||
| MIS | 81.5 (5.1) | 40.5 | – | 73.0 | – | 13.5 | 27 | – | – | – | – | – | 18.1±1.9* |
| TAVI | 84.5 (5.1) | 48.6 | 59.5 | 13.5 | 37.8 | 20.6±2.2* | |||||||
| Haldenwang 201429 | |||||||||||||
| miAVR | 81.9 (4.5) | 57.1 | 31.2 | – | – | – | – | – | – | – | – | 8.7±(6.9)§ | – |
| TA–TAVI | 78.5 (3.4) | 41.1 | 26.8 | 4.5±(5.7)§ | – | ||||||||
| Zierer 200920 | |||||||||||||
| TA–TAVI | 85.0 (6) | 29.0 | 29.0 | – | – | 19.0 | – | 14.0 | 14.0 | – | – | – | 38.0 (14)* |
| PUS–AVR | 82.0 (4) | 37.0 | 23.0 | 10.0 | 5.0 | 0.0 | 35.0 (9)* | ||||||
*Reported as % (range).
†Reported as median % (IQR).
‡Baseline characteristics reported here represent the rapid deployment cohort as a whole, however only 19 patients underwent the procedure through a minimally invasive approach thus were included in the analysis.
§Reported as mean % (SD).
¶Authors did not report baseline characteristics for the cohort.
AF, atrial fibrillation; CS, cardiac surgery; miAVR, minimally invasive aortic valve replacement; MIS, minimally invasive sutureless; MS, ministernotomy; MT, mini-thoracotomy; PCI, percutaneous coronary intervention; PUS, partial upper sternotomy; RD-AVR, rapid-deployment aortic valve replacement; RT, right anterior mini-thoracotomy; SAVR, surgical aortic valve replacement; TA, transapical; TAVI, transcatheter aortic valve implantation; TF, transfemoral.